A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
about
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisAdverse effects of biologics: a network meta-analysis and Cochrane overviewAnakinra for rheumatoid arthritisComparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analyEvasion of inflammasome activation by microbial pathogensComparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression AnalysisAnti-inflammatory properties of a novel peptide interleukin 1 receptor antagonistBiologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.Development of interleukin-1 receptor antagonist mutants with enhanced antagonistic activity in vitro and improved therapeutic efficacy in collagen-induced arthritis.Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice.Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project.Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation.Biologics and heart failure in rheumatoid arthritis: are we any wiser?Interleukin-1 receptor blockade in perinatal brain injury.Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).Blocking interleukin-1 in rheumatic diseasesInterleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectivesAn expanding role for interleukin-1 blockade from gout to cancer.Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials.Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.Rheumatoid arthritis: an overview of new and emerging therapies.Unmet needs in rheumatoid arthritis.Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review.A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.Therapeutics targeting the inflammasome after central nervous system injury.Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysisInforMatrix: treatment of rheumatoid arthritis using biologicals.Combination therapy for rheumatoid arthritis in the era of biologicalsLong-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes.Infectious complications associated with monoclonal antibodies and related small moleculesBiological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
P2860
Q24185797-EA12B062-6150-4C5D-81E0-319D098B13AAQ24234197-87C64B40-A4DC-4DC2-8C31-779AE9CB5462Q24241707-78296A4D-B3BC-49BC-B4C7-382C3598C007Q27694496-F3CC4BB1-84A0-4FFA-98D3-2070E1029A93Q28082757-DE9EAB70-E8E2-4D29-B3FC-DF2F6DF533FFQ28547851-79F64D61-67A6-4583-B684-99FD1C74CD98Q28659160-09EADBB7-B15C-4D6D-86A8-21F918B022D3Q30234528-ADDE55F4-DA33-469A-A904-E0F9D1F0168DQ30235341-2DECB817-64DC-40D6-A890-7B9B994A147FQ31039549-66171A64-C0AC-463A-BED7-02761DA3BD6AQ33315300-12047AC3-6FF8-4917-B8F9-1A97FB3FD693Q33345449-D9128547-1931-4062-995F-07304DF72376Q33369142-F200BA08-4FCD-45EA-BF6D-DAF5175C22F8Q33573112-7448D5BA-4F31-4229-9BC1-1678A7417744Q33848529-65D4F0B5-8FFF-47C6-A872-B5FE2D85D92BQ33898103-06CEE082-617F-415B-A631-019BF0BD5CBFQ34297349-9A3924DD-94CD-4823-A6EF-708F7F833E53Q34758824-0448A463-63AB-4419-81AC-1FC98C258B26Q34822708-B8195C80-2EF7-4855-8C62-4A695535E102Q35133812-19BFC5F7-A513-4B2D-A9EB-680CD0FEB8C2Q35219001-44215149-8D42-461F-8780-08C0BEFBEB77Q35557906-04EF5878-094D-4D0B-B22D-6458BE12EED7Q35579517-94815D18-50F5-4162-BE02-65554E261A2EQ35636722-0F20AB09-DDA3-4241-ADC8-84844668F1EEQ35637379-D17AEA9E-0058-4C49-B99A-9FAE192B1EA3Q36125978-D9A6C847-6C8E-4FD7-AFB6-CCA433736D44Q36160669-6FFF1719-9C3C-4BF0-8C09-04A2A36467A9Q36165321-18FD2F46-A8B9-4C78-944D-552636F0CC61Q36195284-4D4837B9-0095-43D0-A3D2-312CAB0147F5Q36195807-E3826EAD-C24D-45A6-B919-41C5E3E2357CQ36200678-B16B04F0-A901-42BF-A91B-4D381358DB16Q36275988-EBCBA402-CCC1-461B-9865-23288923D61FQ36287541-AA95701E-DB58-47D2-9A32-7B185BC92CDDQ36573901-17180F32-6437-4F40-B9AC-5A58DF0928BAQ36823684-ED0B41DD-ACDC-4BF0-BA4E-CAC9391E6DBCQ37118963-5D4299C5-58C7-4FFB-A97B-F72F23A76950Q37156636-0F239A05-A1A9-44FD-B050-25EC6A6B030BQ37290665-6990DF0E-11C3-4018-958E-60E379BE1960Q37388213-84EE5657-AEA1-4DEF-B3E7-7C0B66F92F0AQ37428436-2D35AF54-8F9E-4A46-8283-C969FA4773A7
P2860
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A multicentre, double blind, r ...... with background methotrexate.
@ast
A multicentre, double blind, r ...... with background methotrexate.
@en
type
label
A multicentre, double blind, r ...... with background methotrexate.
@ast
A multicentre, double blind, r ...... with background methotrexate.
@en
prefLabel
A multicentre, double blind, r ...... with background methotrexate.
@ast
A multicentre, double blind, r ...... with background methotrexate.
@en
P2093
P2860
P356
P1476
A multicentre, double blind, r ...... with background methotrexate.
@en
P2093
990145 Study Group
L W Moreland
M M Kraishi
M W Greenwald
P S Hanrahan
P2860
P304
P356
10.1136/ARD.2003.016014
P407
P577
2004-04-13T00:00:00Z